TY - JOUR
T1 - Moxalactam-tobramycin-resistant Pseudomonas aeruginosa Isolates in Patients with Cystic Fibrosis
AU - Brown Fitzpatrick, Sherahe
AU - Rosenstein, Beryl J.
PY - 1983/9
Y1 - 1983/9
N2 - In vitro studies have shown synergistic killing activity against Pseudomonas aeruginosa (PA) with the combination of an aminoglycoside and moxalactam, a new beta-lactam agent. We describe three patients with cystic fibrosis (CF) with PA isolates that were resistant to all single-agent antibiotics, but sensitive to the combination of moxalactam-tobramycin. Initially, all patients had a good clinical response to this combination. However, during a second course of therapy, there was clinical deterioration coincident with the rapid emergence of moxalactam-tobramycin-resistant PA isolates.
AB - In vitro studies have shown synergistic killing activity against Pseudomonas aeruginosa (PA) with the combination of an aminoglycoside and moxalactam, a new beta-lactam agent. We describe three patients with cystic fibrosis (CF) with PA isolates that were resistant to all single-agent antibiotics, but sensitive to the combination of moxalactam-tobramycin. Initially, all patients had a good clinical response to this combination. However, during a second course of therapy, there was clinical deterioration coincident with the rapid emergence of moxalactam-tobramycin-resistant PA isolates.
UR - http://www.scopus.com/inward/record.url?scp=0020592017&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020592017&partnerID=8YFLogxK
U2 - 10.1177/000992288302200907
DO - 10.1177/000992288302200907
M3 - Article
C2 - 6224623
AN - SCOPUS:0020592017
SN - 0009-9228
VL - 22
SP - 628
EP - 630
JO - Clinical pediatrics
JF - Clinical pediatrics
IS - 9
ER -